Outcomes during follow-up
| Outcome . | Value . |
|---|---|
| Years of follow-up after 1 y of HU treatment, median (range) | 3.9 (0-20.7) |
| Less than 5 y, n (%) | 245 (59) |
| 5-10 y, n (%) | 122 (29) |
| More than 10 y, n (%) | 49 (12) |
| Thrombosis, n (%) | 27 (6.5) |
| AMI | 8 (30) |
| Stroke/TIA | 9 (33) |
| PAT | 2 (7) |
| VTE | 8 (30) |
| Rate of thrombosis, percentage of patients/y | 1.66 |
| Hematologic transformations, n (%) | 16 (3.8) |
| MF | 10 (63) |
| AML | 6 (37) |
| Rate of hematologic transformations, % of patients/y | 0.68 |
| Deaths, n (%) | 23 (5.5) |
| Thrombotic cause | 3 (13) |
| Hemorrhagic cause | 1 (4) |
| Post-ET MF and AML | 6 (26) |
| Solid tumors | 3 (13) |
| Other cause | 10 (43) |
| Rate of deaths, % of patients/y | 0.93 |
| Outcome . | Value . |
|---|---|
| Years of follow-up after 1 y of HU treatment, median (range) | 3.9 (0-20.7) |
| Less than 5 y, n (%) | 245 (59) |
| 5-10 y, n (%) | 122 (29) |
| More than 10 y, n (%) | 49 (12) |
| Thrombosis, n (%) | 27 (6.5) |
| AMI | 8 (30) |
| Stroke/TIA | 9 (33) |
| PAT | 2 (7) |
| VTE | 8 (30) |
| Rate of thrombosis, percentage of patients/y | 1.66 |
| Hematologic transformations, n (%) | 16 (3.8) |
| MF | 10 (63) |
| AML | 6 (37) |
| Rate of hematologic transformations, % of patients/y | 0.68 |
| Deaths, n (%) | 23 (5.5) |
| Thrombotic cause | 3 (13) |
| Hemorrhagic cause | 1 (4) |
| Post-ET MF and AML | 6 (26) |
| Solid tumors | 3 (13) |
| Other cause | 10 (43) |
| Rate of deaths, % of patients/y | 0.93 |
Percentages of different types of thrombosis, hematologic transformations, and cause-specific deaths relate to the total number of thromboses, hematologic transformations, and deaths, respectively.
AMI indicates acute myocardial infarction; TIA, cerebral transient ischemic attack; PAT, peripheral arterial thrombosis; VTE, venous thromboembolism; MF, myelofibrosis; and AML, acute myeloid leukemia.